59 185

Cited 6 times in

Von Hippel-Lindau regulates interleukin-32β stability in ovarian cancer cells

DC Field Value Language
dc.contributor.author박정수-
dc.date.accessioned2023-08-09T02:48:08Z-
dc.date.available2023-08-09T02:48:08Z-
dc.date.issued2017-09-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195851-
dc.description.abstractHypoxia-induced interleukin-32β (IL-32β) shifts the metabolic program to the enhanced glycolytic pathway. In the present study, the underlying mechanism by which hypoxia-induced IL-32β stability is regulated was investigated in ovarian cancer cells. IL-32β expression increased under hypoxic conditions in ovarian cancer cells as it did in breast cancer cells. The amount of IL-32β was regulated by post-translational control rather than by transcriptional activation. Under normoxic conditions, IL-32β was continuously eliminated through ubiquitin-dependent degradation by the von-Hippel Lindau (VHL) E3 ligase complex. Oxygen deficiency or reactive oxygen species (ROS) disrupted the interaction between IL-32β and VHL, leading to the accumulation of the cytokine. The fact that IL-32β is regulated by the energy-consuming ubiquitination system implies that it plays an important role in oxidative stress. We found that IL-32β reduced protein kinase Cδ (PKCδ)-induced apoptosis under oxidative stress. This implies that the hypoxia- and ROS-stabilized IL-32β contributes to sustain survival against PKCδ-induced apoptosis.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherImpact Journals-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleVon Hippel-Lindau regulates interleukin-32β stability in ovarian cancer cells-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentBioMedical Science Institute (의생명과학부)-
dc.contributor.googleauthorHyo Jeong Yong-
dc.contributor.googleauthorJeong Su Park-
dc.contributor.googleauthorAe Lee Jeong-
dc.contributor.googleauthorSora Han-
dc.contributor.googleauthorSunyi Lee-
dc.contributor.googleauthorHye In Ka-
dc.contributor.googleauthorBuyanravjkh Sumiyasuren-
dc.contributor.googleauthorHyun Jeong Joo-
dc.contributor.googleauthorSu Jeong So-
dc.contributor.googleauthorJi Young Park-
dc.contributor.googleauthorDo-Young Yoon-
dc.contributor.googleauthorJong-Seok Lim-
dc.contributor.googleauthorMyeong-Seok Lee-
dc.contributor.googleauthorHee Gu Lee-
dc.contributor.googleauthorYoung Yang-
dc.identifier.doi10.18632/oncotarget.19311-
dc.contributor.localIdA01645-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid29050245-
dc.subject.keywordapoptosis-
dc.subject.keywordhypoxia-
dc.subject.keywordinterleukin-32-
dc.subject.keywordprotein kinase C-
dc.subject.keywordvon Hippel-Lindau-
dc.contributor.alternativeNamePark, Jeong Su-
dc.contributor.affiliatedAuthor박정수-
dc.citation.volume8-
dc.citation.number41-
dc.citation.startPage69833-
dc.citation.endPage69846-
dc.identifier.bibliographicCitationONCOTARGET, Vol.8(41) : 69833-69846, 2017-09-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.